Nimodipine-d₇is intended for use as an internal standard for the quantification of nimodipine by GC- or LC-MS. Nimodipine is an inhibitor of L-type voltage-gated calcium (Ca_v) channels.¹It is selective for Ca_v1.2 over Ca_v1.3 channels (IC₅₀s = 0.139 and 2.7 µM, respectively), as well as R-, N-, and P/Q-type Ca_vchannels at 10 µM.^1,2Nimodipine (0.72-24 nM) inhibits contractions induced by potassium, but not norepinephrine, in isolated rabbit aortic strips.³It increases cerebral blood flow in anesthetized dogs when administered sublingually at doses ranging from 0.01 to 1 mg/kg. Nimodipine decreases necrosis of hippocampal CA1 pyramidal neurons and reduces increases in spontaneous movement and contralateral circling in a rat model of focal cerebral ischemia induced by middle cerebral artery occlusion (MCAO).⁴

1.Furukawa, T., Yamakawa, T., Midera, T., et al.Selectivities of dihydropyridine derivatives in blocking Ca2+ channel subtypes expressed in Xenopus oocytesJ. Pharmacol. Exp. Ther.291(2)464-473(1999) 2.Xu, W., and Lipscombe, D.Neuronal Cav1.3ɑ1 L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridinesJ. Neurosci.21(16)5944-5951(2001) 3.Kazda, S., and Towart, R.Nimodipine: A new calcium antagonistic drug with a preferential cerebrovascular actionActa Neurochir. (Wien)63(1-4)259-265(1982) 4.Babu, C.S., and Ramanathan, M.Post-ischemic administration of nimodipine following focal cerebral ischemic-reperfusion injury in rats alleviated excitotoxicity, neurobehavioural alterations and partially the bioenergeticsInt. J. Dev. Neurosci.29(1)93-105(2011)